Network meta-analysis

Acute pancreatitis

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

Randomized trials

Treatments

51,275

Participants

Events

In plain language

Across 79 trials with 51,275 participants, 2 of 35 treatments had a clearly better result than placebo on acute pancreatitis, and for 33 the evidence could not tell them apart from placebo. The most favorable estimate was for Semaglutide tablet: hazard ratio (from event counts) 0.18 (95% credible interval 0.02 to 1.45).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Semaglutide tablet SEMA_PO	0.18 (0.02 to 1.45)	0.01 to 1.99	Unclear
Insulin glargine INS_GLARGINE	0.19 (0.03 to 0.99)	0.02 to 1.41	Better
Sitagliptin SITAGLIPTIN	0.19 (0.02 to 1.51)	0.01 to 2.28	Unclear
Liraglutide injection LIRA_SC	0.21 (0.04 to 0.83)	0.02 to 1.38	Better
Insulin degludec with liraglutide injection IDEGLIRA_SC	0.24 (0.02 to 2.29)	0.02 to 3.34	Unclear
Exenatide injection EXEN_SC	0.25 (0.02 to 2.10)	0.01 to 3.09	Unclear
Lixisenatide injection LIXI_SC	0.26 (0.02 to 2.48)	0.02 to 3.48	Unclear
Taspoglutide injection TASP_SC	0.31 (0.03 to 3.43)	0.02 to 4.92	Unclear
Glimepiride GLIMEPIRIDE	0.40 (0.04 to 3.59)	0.03 to 5.14	Unclear
Insulin degludec INS_DEGLUDEC	0.41 (0.03 to 5.09)	0.02 to 7.08	Unclear
Insulin lispro (prandial) INS_LISPRO	0.41 (0.03 to 4.53)	0.02 to 6.14	Unclear
Semaglutide injection SEMA_SC	0.44 (0.10 to 1.83)	0.06 to 2.97	Unclear
Metformin METFORMIN	0.48 (0.04 to 5.71)	0.02 to 7.76	Unclear
Dapagliflozin DAPAGLIFLOZIN	0.53 (0.04 to 6.29)	0.03 to 8.66	Unclear
Loti po LOTI_PO	0.62 (0.04 to 9.86)	0.03 to 12.91	Unclear
Insulin glargine with lixisenatide injection IGLARLIXI_SC	0.62 (0.04 to 9.68)	0.03 to 14.13	Unclear
Danuglipron tablet DANU_PO	0.62 (0.04 to 10.34)	0.03 to 13.26	Unclear
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.64 (0.04 to 10.67)	0.03 to 14.81	Unclear
Dulaglutide injection DULA_SC	0.65 (0.13 to 1.75)	0.06 to 2.61	Unclear
Ecnoglutide injection ECNO_SC	0.66 (0.04 to 11.40)	0.03 to 14.95	Unclear
Polyethylene glycol loxenatide injection PEGLOX_SC	0.66 (0.04 to 11.75)	0.03 to 14.43	Unclear
Vildagliptin VILDAGLIPTIN	0.66 (0.04 to 11.04)	0.03 to 13.85	Unclear
Orforglipron tablet ORFO_PO	0.68 (0.04 to 10.94)	0.03 to 14.70	Unclear
HRS-7535 tablet HRS7535_PO	0.68 (0.05 to 10.25)	0.03 to 13.45	Unclear
Bofanglutide (GZR18) injection BOFANG_SC	0.70 (0.04 to 11.27)	0.03 to 14.19	Unclear
Mazdutide injection MAZD_SC	0.71 (0.04 to 10.97)	0.03 to 14.57	Unclear
Additional oad OTHER_ACTIVE_additional_OAD	0.74 (0.05 to 11.51)	0.04 to 15.11	Unclear
Visepegenatide injection VISEPE_SC	0.74 (0.04 to 10.40)	0.03 to 14.73	Unclear
Standard care or no added treatment STANDARD_CARE	0.74 (0.04 to 13.23)	0.03 to 17.79	Unclear
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	0.77 (0.04 to 12.23)	0.04 to 16.58	Unclear
Efpe sc EFPE_SC	0.83 (0.09 to 8.84)	0.06 to 12.70	Unclear
Safiglipron (HRS-7535) tablet SAFIGL_PO	0.92 (0.11 to 8.34)	0.07 to 12.26	Unclear
Albiglutide injection ALBI_SC	1.01 (0.25 to 3.24)	0.13 to 5.69	Unclear
Exenatide extended release injection EXENER_SC	1.01 (0.14 to 7.48)	0.09 to 10.85	Unclear
Tirzepatide injection TIRZ_SC	1.39 (0.16 to 13.37)	0.11 to 17.99	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	SEMA_PO	INS_GLARGINE	SITAGLIPTIN	LIRA_SC	IDEGLIRA_SC	EXEN_SC	LIXI_SC	TASP_SC	GLIMEPIRIDE	INS_DEGLUDEC	INS_LISPRO	SEMA_SC	METFORMIN	DAPAGLIFLOZIN	LOTI_PO	IGLARLIXI_SC	DANU_PO	OTHER_ACTIVE_sulfonylurea	DULA_SC	ECNO_SC	PEGLOX_SC	VILDAGLIPTIN	ORFO_PO	HRS7535_PO	BOFANG_SC	MAZD_SC	OTHER_ACTIVE_additional_OAD	VISEPE_SC	STANDARD_CARE	OTHER_ACTIVE_basal_bolus_insulin	EFPE_SC	SAFIGL_PO	ALBI_SC	EXENER_SC	TIRZ_SC
PLACEBO	PLACEBO	5.67 0.69 to 56.76	5.32 1.01 to 36.33	5.23 0.66 to 53.73	4.75 1.20 to 24.40	4.23 0.44 to 46.08	4.01 0.48 to 47.53	3.85 0.40 to 42.39	3.23 0.29 to 39.08	2.50 0.28 to 22.80	2.46 0.20 to 36.24	2.45 0.22 to 32.01	2.26 0.55 to 9.92	2.07 0.18 to 28.38	1.88 0.16 to 26.55	1.62 0.10 to 26.46	1.61 0.10 to 24.52	1.60 0.10 to 24.03	1.56 0.09 to 24.24	1.54 0.57 to 7.70	1.52 0.09 to 23.45	1.51 0.09 to 26.79	1.50 0.09 to 24.88	1.48 0.09 to 24.07	1.47 0.10 to 22.09	1.42 0.09 to 23.42	1.42 0.09 to 22.58	1.35 0.09 to 20.84	1.35 0.10 to 22.42	1.35 0.08 to 24.09	1.30 0.08 to 22.25	1.20 0.11 to 11.39	1.08 0.12 to 9.17	0.99 0.31 to 4.06	0.99 0.13 to 7.38	0.72 0.07 to 6.35
SEMA_PO	0.18 0.02 to 1.45	SEMA_PO	0.94 0.06 to 15.05	0.89 0.04 to 21.91	0.84 0.06 to 11.46	0.74 0.03 to 17.43	0.71 0.03 to 17.02	0.67 0.03 to 16.31	0.57 0.02 to 15.87	0.42 0.02 to 8.80	0.43 0.01 to 13.24	0.42 0.02 to 10.43	0.39 0.03 to 5.18	0.36 0.01 to 9.80	0.32 0.01 to 9.64	0.28 0.01 to 9.19	0.27 0.01 to 8.56	0.28 0.01 to 8.70	0.27 0.01 to 8.48	0.29 0.02 to 3.49	0.26 0.01 to 8.38	0.26 0.01 to 9.29	0.25 0.01 to 8.02	0.25 0.01 to 8.09	0.26 0.01 to 8.18	0.25 0.01 to 7.98	0.24 0.01 to 8.18	0.22 0.01 to 7.69	0.23 0.01 to 8.41	0.23 0.01 to 8.40	0.22 0.01 to 7.12	0.20 0.01 to 4.50	0.19 0.01 to 3.55	0.17 0.01 to 2.09	0.17 0.01 to 3.06	0.12 0.01 to 2.58
INS_GLARGINE	0.19 0.03 to 0.99	1.06 0.07 to 18.03	INS_GLARGINE	0.96 0.06 to 16.02	0.90 0.08 to 8.75	0.79 0.04 to 13.06	0.75 0.05 to 13.50	0.72 0.04 to 12.92	0.59 0.03 to 11.91	0.46 0.03 to 7.04	0.46 0.02 to 9.80	0.45 0.02 to 10.43	0.42 0.05 to 2.98	0.38 0.02 to 9.52	0.34 0.02 to 7.79	0.30 0.01 to 7.67	0.29 0.01 to 7.24	0.28 0.01 to 7.26	0.28 0.01 to 7.49	0.31 0.04 to 1.99	0.27 0.01 to 6.58	0.27 0.01 to 7.87	0.27 0.01 to 7.10	0.27 0.01 to 7.33	0.28 0.01 to 6.61	0.26 0.01 to 6.67	0.26 0.01 to 6.41	0.24 0.01 to 6.07	0.24 0.01 to 6.64	0.24 0.01 to 7.21	0.23 0.01 to 6.43	0.22 0.01 to 3.63	0.20 0.01 to 3.23	0.19 0.02 to 1.47	0.18 0.01 to 2.20	0.13 0.01 to 1.98
SITAGLIPTIN	0.19 0.02 to 1.51	1.13 0.05 to 23.67	1.04 0.06 to 16.25	SITAGLIPTIN	0.91 0.06 to 12.02	0.80 0.03 to 17.73	0.77 0.03 to 20.89	0.73 0.03 to 15.60	0.62 0.02 to 14.95	0.46 0.02 to 9.93	0.46 0.02 to 14.72	0.46 0.02 to 12.46	0.44 0.03 to 4.25	0.39 0.01 to 11.23	0.36 0.01 to 10.14	0.31 0.01 to 9.41	0.29 0.01 to 9.21	0.30 0.01 to 9.89	0.29 0.01 to 8.84	0.31 0.02 to 4.11	0.29 0.01 to 8.18	0.28 0.01 to 10.24	0.28 0.01 to 9.31	0.27 0.01 to 9.16	0.28 0.01 to 8.60	0.27 0.01 to 8.86	0.26 0.01 to 8.00	0.25 0.01 to 7.68	0.26 0.01 to 8.46	0.25 0.01 to 8.83	0.24 0.01 to 7.79	0.22 0.01 to 5.13	0.20 0.01 to 3.96	0.19 0.01 to 2.24	0.19 0.01 to 3.02	0.13 0.01 to 2.83
LIRA_SC	0.21 0.04 to 0.83	1.19 0.09 to 17.26	1.11 0.11 to 12.43	1.10 0.08 to 15.83	LIRA_SC	0.87 0.06 to 13.79	0.83 0.06 to 13.12	0.80 0.05 to 14.11	0.67 0.03 to 11.60	0.51 0.05 to 4.81	0.52 0.03 to 10.18	0.50 0.03 to 9.08	0.47 0.06 to 3.53	0.43 0.02 to 8.55	0.39 0.02 to 7.78	0.34 0.01 to 7.78	0.33 0.01 to 6.94	0.32 0.01 to 6.69	0.32 0.01 to 7.19	0.34 0.05 to 2.37	0.31 0.01 to 6.87	0.31 0.01 to 7.56	0.30 0.01 to 6.51	0.29 0.01 to 6.75	0.30 0.01 to 7.05	0.30 0.01 to 6.67	0.29 0.01 to 6.52	0.27 0.01 to 6.03	0.27 0.01 to 6.75	0.27 0.01 to 7.10	0.26 0.01 to 6.05	0.24 0.01 to 3.42	0.22 0.01 to 2.95	0.21 0.03 to 1.41	0.20 0.02 to 2.07	0.15 0.01 to 1.99
IDEGLIRA_SC	0.24 0.02 to 2.29	1.35 0.06 to 36.89	1.27 0.08 to 23.32	1.25 0.06 to 33.12	1.15 0.07 to 17.39	IDEGLIRA_SC	1.00 0.04 to 25.30	0.91 0.03 to 25.22	0.76 0.03 to 23.17	0.57 0.02 to 13.96	0.58 0.03 to 14.15	0.57 0.02 to 18.23	0.53 0.03 to 8.02	0.49 0.02 to 17.59	0.44 0.01 to 13.61	0.39 0.01 to 13.61	0.37 0.01 to 13.04	0.37 0.01 to 13.97	0.37 0.01 to 13.30	0.40 0.03 to 5.45	0.35 0.01 to 12.75	0.36 0.01 to 13.18	0.36 0.01 to 13.11	0.34 0.01 to 14.40	0.34 0.01 to 12.93	0.33 0.01 to 13.29	0.34 0.01 to 11.73	0.31 0.01 to 11.19	0.31 0.01 to 11.85	0.31 0.01 to 12.32	0.31 0.01 to 11.63	0.27 0.01 to 7.27	0.25 0.01 to 5.65	0.24 0.02 to 3.41	0.24 0.01 to 5.02	0.17 0.01 to 3.92
EXEN_SC	0.25 0.02 to 2.10	1.40 0.06 to 29.38	1.34 0.07 to 21.68	1.30 0.05 to 30.99	1.20 0.08 to 16.89	1.00 0.04 to 26.19	EXEN_SC	0.95 0.04 to 22.49	0.79 0.02 to 22.13	0.62 0.02 to 12.31	0.61 0.02 to 17.26	0.60 0.02 to 17.15	0.56 0.03 to 7.30	0.50 0.02 to 15.74	0.47 0.01 to 14.00	0.39 0.01 to 13.51	0.38 0.01 to 12.82	0.38 0.01 to 13.61	0.38 0.01 to 12.44	0.41 0.03 to 4.48	0.35 0.01 to 12.18	0.36 0.01 to 12.92	0.36 0.01 to 12.61	0.35 0.01 to 11.93	0.36 0.01 to 11.70	0.34 0.01 to 11.66	0.35 0.01 to 11.35	0.31 0.01 to 11.17	0.32 0.01 to 11.63	0.32 0.01 to 10.93	0.32 0.01 to 11.03	0.29 0.01 to 6.26	0.26 0.01 to 5.38	0.25 0.02 to 2.98	0.23 0.01 to 4.62	0.17 0.01 to 3.51
LIXI_SC	0.26 0.02 to 2.48	1.49 0.06 to 37.13	1.39 0.08 to 25.34	1.36 0.06 to 31.14	1.25 0.07 to 19.56	1.10 0.04 to 28.61	1.05 0.04 to 26.64	LIXI_SC	0.82 0.03 to 23.47	0.64 0.02 to 14.79	0.63 0.02 to 20.68	0.63 0.02 to 20.07	0.58 0.03 to 8.38	0.53 0.02 to 18.47	0.46 0.02 to 14.98	0.42 0.01 to 14.35	0.40 0.01 to 14.94	0.42 0.01 to 13.46	0.39 0.01 to 15.23	0.43 0.03 to 6.32	0.38 0.01 to 13.72	0.39 0.01 to 14.64	0.38 0.01 to 13.85	0.37 0.01 to 13.05	0.36 0.01 to 13.18	0.36 0.01 to 12.57	0.36 0.01 to 12.89	0.33 0.01 to 12.79	0.35 0.01 to 13.14	0.34 0.01 to 13.24	0.33 0.01 to 13.20	0.30 0.01 to 7.70	0.28 0.01 to 6.30	0.26 0.02 to 3.65	0.25 0.01 to 5.19	0.18 0.01 to 4.10
TASP_SC	0.31 0.03 to 3.43	1.77 0.06 to 52.14	1.69 0.08 to 33.37	1.62 0.07 to 46.44	1.49 0.09 to 28.92	1.32 0.04 to 38.42	1.27 0.05 to 41.91	1.22 0.04 to 37.50	TASP_SC	0.78 0.02 to 22.81	0.78 0.02 to 27.79	0.76 0.02 to 25.54	0.68 0.04 to 12.02	0.65 0.02 to 24.89	0.58 0.02 to 20.27	0.51 0.01 to 20.89	0.49 0.01 to 18.18	0.48 0.01 to 20.35	0.49 0.01 to 20.01	0.52 0.03 to 8.47	0.46 0.01 to 19.43	0.46 0.01 to 20.80	0.47 0.01 to 18.87	0.45 0.01 to 18.42	0.47 0.01 to 18.84	0.46 0.01 to 18.05	0.44 0.01 to 16.89	0.41 0.01 to 15.16	0.42 0.01 to 16.28	0.41 0.01 to 17.60	0.41 0.01 to 16.78	0.37 0.01 to 10.19	0.33 0.01 to 8.81	0.32 0.02 to 5.01	0.31 0.01 to 7.51	0.22 0.01 to 5.81
GLIMEPIRIDE	0.40 0.04 to 3.59	2.38 0.11 to 52.77	2.17 0.14 to 39.51	2.16 0.10 to 47.77	1.95 0.21 to 21.10	1.77 0.07 to 41.26	1.60 0.08 to 40.69	1.56 0.07 to 42.76	1.28 0.04 to 41.35	GLIMEPIRIDE	1.00 0.03 to 29.04	0.98 0.04 to 27.00	0.91 0.07 to 12.32	0.83 0.03 to 23.81	0.77 0.03 to 23.10	0.67 0.02 to 20.18	0.64 0.02 to 21.56	0.61 0.02 to 21.21	0.63 0.02 to 20.57	0.65 0.06 to 8.81	0.61 0.02 to 20.70	0.60 0.02 to 23.74	0.59 0.02 to 19.04	0.58 0.02 to 19.88	0.59 0.02 to 20.88	0.58 0.02 to 19.21	0.57 0.02 to 18.81	0.53 0.02 to 18.16	0.53 0.02 to 19.59	0.54 0.01 to 20.24	0.51 0.02 to 18.09	0.48 0.02 to 11.54	0.43 0.02 to 9.81	0.41 0.03 to 5.32	0.39 0.02 to 7.27	0.29 0.01 to 6.22
INS_DEGLUDEC	0.41 0.03 to 5.09	2.31 0.08 to 71.12	2.19 0.10 to 49.54	2.16 0.07 to 64.51	1.94 0.10 to 39.33	1.72 0.07 to 37.43	1.63 0.06 to 49.78	1.58 0.05 to 51.67	1.28 0.04 to 46.34	1.00 0.03 to 29.40	INS_DEGLUDEC	0.99 0.03 to 35.78	0.92 0.05 to 17.17	0.85 0.02 to 37.62	0.74 0.02 to 27.94	0.65 0.01 to 27.58	0.63 0.01 to 28.59	0.64 0.01 to 29.09	0.64 0.01 to 25.74	0.66 0.04 to 12.49	0.61 0.01 to 23.69	0.62 0.01 to 27.82	0.58 0.01 to 25.30	0.58 0.01 to 26.58	0.59 0.01 to 25.12	0.56 0.01 to 24.70	0.55 0.01 to 25.40	0.53 0.01 to 24.46	0.55 0.01 to 25.24	0.55 0.01 to 22.82	0.53 0.01 to 21.58	0.47 0.01 to 15.45	0.44 0.01 to 12.55	0.42 0.02 to 7.03	0.38 0.01 to 9.15	0.28 0.01 to 8.96
INS_LISPRO	0.41 0.03 to 4.53	2.36 0.10 to 61.50	2.23 0.10 to 47.83	2.16 0.08 to 62.43	2.00 0.11 to 36.89	1.76 0.05 to 48.86	1.65 0.06 to 51.43	1.59 0.05 to 51.01	1.32 0.04 to 40.80	1.02 0.04 to 27.22	1.01 0.03 to 35.75	INS_LISPRO	0.94 0.05 to 16.52	0.85 0.03 to 29.33	0.78 0.02 to 27.09	0.67 0.02 to 26.94	0.64 0.02 to 25.48	0.64 0.01 to 26.96	0.62 0.01 to 27.00	0.68 0.04 to 11.24	0.60 0.01 to 23.70	0.61 0.01 to 25.85	0.60 0.01 to 25.78	0.57 0.01 to 24.86	0.59 0.02 to 24.27	0.58 0.01 to 24.16	0.58 0.01 to 21.88	0.54 0.01 to 21.87	0.55 0.01 to 20.13	0.54 0.01 to 26.28	0.53 0.01 to 20.16	0.48 0.02 to 13.38	0.44 0.01 to 10.24	0.42 0.03 to 5.29	0.39 0.01 to 8.79	0.30 0.01 to 7.17
SEMA_SC	0.44 0.10 to 1.83	2.54 0.19 to 37.69	2.38 0.34 to 20.13	2.28 0.24 to 30.82	2.14 0.28 to 17.44	1.87 0.12 to 29.33	1.79 0.14 to 30.25	1.72 0.12 to 29.02	1.46 0.08 to 25.41	1.09 0.08 to 13.88	1.08 0.06 to 21.04	1.07 0.06 to 19.54	SEMA_SC	0.93 0.06 to 17.60	0.82 0.04 to 15.93	0.72 0.03 to 16.12	0.70 0.03 to 14.40	0.70 0.03 to 15.45	0.68 0.03 to 15.71	0.72 0.13 to 5.18	0.68 0.03 to 14.30	0.65 0.02 to 15.16	0.67 0.03 to 14.50	0.64 0.03 to 15.49	0.64 0.03 to 13.71	0.64 0.03 to 13.76	0.63 0.03 to 13.93	0.59 0.03 to 12.27	0.59 0.03 to 13.66	0.58 0.02 to 13.88	0.57 0.03 to 12.56	0.52 0.04 to 7.35	0.48 0.04 to 6.09	0.44 0.07 to 2.99	0.43 0.04 to 4.89	0.31 0.02 to 4.14
METFORMIN	0.48 0.04 to 5.71	2.80 0.10 to 81.99	2.67 0.11 to 65.60	2.55 0.09 to 75.14	2.34 0.12 to 42.35	2.06 0.06 to 61.90	2.01 0.06 to 59.41	1.89 0.05 to 59.08	1.55 0.04 to 47.91	1.20 0.04 to 31.49	1.18 0.03 to 47.64	1.18 0.03 to 39.30	1.08 0.06 to 17.52	METFORMIN	0.90 0.02 to 33.05	0.80 0.02 to 32.31	0.78 0.02 to 29.60	0.76 0.02 to 29.25	0.76 0.02 to 30.89	0.79 0.05 to 12.93	0.71 0.02 to 30.83	0.73 0.02 to 28.58	0.70 0.01 to 31.35	0.72 0.02 to 29.10	0.71 0.02 to 29.59	0.66 0.02 to 30.19	0.67 0.02 to 30.26	0.64 0.01 to 25.67	0.64 0.02 to 26.81	0.64 0.01 to 27.49	0.62 0.01 to 25.07	0.58 0.02 to 16.39	0.53 0.02 to 13.24	0.50 0.03 to 7.73	0.47 0.02 to 11.38	0.33 0.01 to 8.98
DAPAGLIFLOZIN	0.53 0.04 to 6.29	3.11 0.10 to 100	2.92 0.13 to 64.37	2.82 0.10 to 81.52	2.56 0.13 to 51.82	2.26 0.07 to 68.33	2.13 0.07 to 67.68	2.18 0.07 to 66.55	1.74 0.05 to 61.13	1.31 0.04 to 38.74	1.34 0.04 to 51.74	1.28 0.04 to 47.80	1.22 0.06 to 22.77	1.11 0.03 to 43.77	DAPAGLIFLOZIN	0.87 0.02 to 38.52	0.83 0.02 to 33.96	0.85 0.02 to 35.15	0.82 0.02 to 34.91	0.88 0.05 to 15.98	0.82 0.02 to 29.45	0.78 0.02 to 37.35	0.79 0.02 to 33.47	0.76 0.02 to 31.71	0.77 0.02 to 32.10	0.73 0.02 to 32.47	0.76 0.02 to 32.21	0.69 0.02 to 29.11	0.72 0.02 to 32.59	0.70 0.02 to 35.53	0.69 0.02 to 27.34	0.62 0.02 to 18.00	0.60 0.02 to 10.13	0.53 0.03 to 9.10	0.51 0.02 to 12.13	0.38 0.01 to 9.54
LOTI_PO	0.62 0.04 to 9.86	3.53 0.11 to 121	3.30 0.13 to 95.53	3.18 0.11 to 121	2.95 0.13 to 74.83	2.57 0.07 to 95.39	2.55 0.07 to 97.24	2.39 0.07 to 80.11	1.95 0.05 to 79.64	1.50 0.05 to 55.72	1.53 0.04 to 69.44	1.49 0.04 to 65.47	1.40 0.06 to 29.43	1.25 0.03 to 55.12	1.14 0.03 to 49.61	LOTI_PO	0.95 0.02 to 46.52	0.96 0.02 to 49.53	0.94 0.02 to 46.08	1.00 0.05 to 22.31	0.91 0.02 to 41.28	0.91 0.02 to 50.31	0.91 0.02 to 42.92	0.87 0.02 to 44.54	0.89 0.02 to 46.29	0.83 0.02 to 40.63	0.85 0.02 to 43.33	0.82 0.02 to 41.99	0.82 0.02 to 43.49	0.83 0.02 to 42.15	0.78 0.02 to 39.90	0.74 0.02 to 24.43	0.68 0.02 to 21.44	0.60 0.03 to 12.68	0.59 0.02 to 18.41	0.44 0.01 to 14.00
IGLARLIXI_SC	0.62 0.04 to 9.68	3.71 0.12 to 127	3.40 0.14 to 92.86	3.41 0.11 to 117	3.03 0.14 to 69.62	2.67 0.08 to 102	2.63 0.08 to 105	2.53 0.07 to 94.29	2.05 0.05 to 86.31	1.57 0.05 to 57.35	1.59 0.03 to 73.77	1.55 0.04 to 65.09	1.43 0.07 to 32.19	1.29 0.03 to 55.03	1.21 0.03 to 49.27	1.05 0.02 to 54.06	IGLARLIXI_SC	1.00 0.02 to 52.57	0.96 0.02 to 54.75	1.05 0.05 to 23.25	0.94 0.02 to 46.15	0.93 0.02 to 50.76	0.95 0.02 to 53.58	0.90 0.02 to 48.42	0.94 0.02 to 44.35	0.90 0.02 to 44.69	0.89 0.02 to 46.30	0.83 0.02 to 40.13	0.87 0.02 to 41.55	0.83 0.02 to 44.99	0.80 0.02 to 41.65	0.77 0.02 to 26.25	0.68 0.02 to 22.42	0.65 0.03 to 12.99	0.61 0.02 to 19.31	0.44 0.01 to 14.26
DANU_PO	0.62 0.04 to 10.34	3.59 0.11 to 136	3.52 0.14 to 98.93	3.32 0.10 to 123	3.09 0.15 to 69.81	2.72 0.07 to 99.75	2.64 0.07 to 97.01	2.40 0.07 to 93.77	2.10 0.05 to 84.48	1.63 0.05 to 50.07	1.55 0.03 to 73.34	1.56 0.04 to 67.81	1.43 0.06 to 32.25	1.31 0.03 to 55.36	1.18 0.03 to 50.76	1.04 0.02 to 51.93	1.00 0.02 to 49.64	DANU_PO	0.95 0.02 to 52.66	1.05 0.05 to 23.08	0.95 0.02 to 47.50	0.92 0.02 to 53.56	0.90 0.02 to 49.64	0.91 0.02 to 43.97	0.95 0.02 to 38.86	0.89 0.02 to 48.60	0.91 0.02 to 42.92	0.82 0.02 to 38.19	0.84 0.02 to 45.12	0.85 0.01 to 47.56	0.82 0.02 to 44.71	0.75 0.02 to 27.52	0.67 0.02 to 21.34	0.64 0.03 to 13.70	0.61 0.02 to 19.87	0.45 0.01 to 15.75
OTHER_ACTIVE_sulfonylurea	0.64 0.04 to 10.67	3.72 0.12 to 137	3.55 0.13 to 106	3.45 0.11 to 134	3.13 0.14 to 82.64	2.74 0.08 to 104	2.65 0.08 to 96.40	2.59 0.07 to 96.67	2.03 0.05 to 87.50	1.58 0.05 to 56.45	1.56 0.04 to 75.69	1.61 0.04 to 73.75	1.47 0.06 to 34.20	1.32 0.03 to 64.28	1.23 0.03 to 51.74	1.06 0.02 to 61.44	1.04 0.02 to 56.56	1.05 0.02 to 52.48	OTHER_ACTIVE_sulfonylurea	1.04 0.05 to 24.94	0.96 0.02 to 43.38	0.95 0.02 to 51.29	0.95 0.02 to 52.18	0.93 0.02 to 49.52	0.94 0.02 to 48.06	0.91 0.02 to 48.60	0.93 0.02 to 44.42	0.87 0.02 to 44.18	0.87 0.02 to 47.27	0.86 0.02 to 48.89	0.83 0.02 to 41.08	0.74 0.02 to 29.18	0.71 0.02 to 22.26	0.65 0.03 to 13.90	0.61 0.02 to 17.80	0.46 0.01 to 15.22
DULA_SC	0.65 0.13 to 1.75	3.49 0.29 to 45.53	3.23 0.50 to 24.63	3.18 0.24 to 42.21	2.98 0.42 to 18.73	2.51 0.18 to 35.27	2.45 0.22 to 31.77	2.33 0.16 to 34.34	1.94 0.12 to 31.65	1.53 0.11 to 17.47	1.50 0.08 to 26.42	1.47 0.09 to 23.13	1.39 0.19 to 7.74	1.26 0.08 to 21.14	1.13 0.06 to 19.44	1.00 0.04 to 21.32	0.96 0.04 to 19.09	0.95 0.04 to 18.67	0.96 0.04 to 18.66	DULA_SC	0.91 0.04 to 17.32	0.91 0.03 to 20.16	0.90 0.04 to 19.04	0.87 0.04 to 18.79	0.88 0.04 to 17.14	0.86 0.04 to 17.69	0.87 0.04 to 16.06	0.79 0.04 to 16.18	0.79 0.04 to 16.21	0.81 0.03 to 17.71	0.77 0.04 to 15.67	0.73 0.05 to 9.17	0.66 0.05 to 7.11	0.64 0.09 to 2.78	0.60 0.05 to 5.67	0.44 0.03 to 4.52
ECNO_SC	0.66 0.04 to 11.40	3.84 0.12 to 140	3.66 0.15 to 110	3.49 0.12 to 119	3.24 0.15 to 78.30	2.88 0.08 to 105	2.87 0.08 to 108	2.60 0.07 to 99.38	2.19 0.05 to 90.50	1.64 0.05 to 62.86	1.64 0.04 to 74.13	1.67 0.04 to 66.94	1.48 0.07 to 35.02	1.41 0.03 to 65.11	1.22 0.03 to 53.37	1.10 0.02 to 52.42	1.06 0.02 to 55.85	1.06 0.02 to 57.56	1.05 0.02 to 50.10	1.10 0.06 to 26.65	ECNO_SC	1.02 0.02 to 58.47	0.97 0.02 to 54.99	0.99 0.02 to 46.20	0.99 0.02 to 46.59	0.94 0.02 to 52.57	0.91 0.02 to 48.83	0.88 0.02 to 45.60	0.91 0.02 to 49.07	0.88 0.02 to 50.65	0.87 0.02 to 50.31	0.78 0.02 to 28.58	0.71 0.02 to 24.73	0.67 0.03 to 16.14	0.65 0.02 to 20.75	0.49 0.01 to 16.16
PEGLOX_SC	0.66 0.04 to 11.75	3.91 0.11 to 143	3.70 0.13 to 112	3.57 0.10 to 135	3.25 0.13 to 86.45	2.78 0.08 to 126	2.76 0.08 to 115	2.58 0.07 to 111	2.20 0.05 to 95.33	1.67 0.04 to 57.48	1.62 0.04 to 84.25	1.64 0.04 to 73.51	1.54 0.07 to 40.88	1.37 0.03 to 58.97	1.28 0.03 to 61.76	1.10 0.02 to 59.68	1.07 0.02 to 57.59	1.09 0.02 to 53.28	1.05 0.02 to 61.51	1.10 0.05 to 29.48	0.98 0.02 to 54.89	PEGLOX_SC	0.98 0.02 to 56.70	0.96 0.02 to 50.46	0.99 0.02 to 55.01	0.95 0.02 to 47.25	0.96 0.02 to 53.36	0.91 0.02 to 48.13	0.89 0.02 to 49.52	0.91 0.02 to 49.30	0.86 0.02 to 49.52	0.79 0.02 to 32.23	0.72 0.02 to 26.38	0.67 0.03 to 16.75	0.66 0.02 to 22.35	0.48 0.01 to 18.11
VILDAGLIPTIN	0.66 0.04 to 11.04	3.96 0.12 to 152	3.70 0.14 to 101	3.57 0.11 to 140	3.32 0.15 to 76.09	2.80 0.08 to 108	2.81 0.08 to 108	2.65 0.07 to 111	2.14 0.05 to 99.24	1.69 0.05 to 56.30	1.71 0.04 to 74.92	1.68 0.04 to 72.05	1.49 0.07 to 37.91	1.42 0.03 to 73.39	1.27 0.03 to 64.87	1.10 0.02 to 58.55	1.06 0.02 to 55.42	1.11 0.02 to 44.43	1.05 0.02 to 57.60	1.11 0.05 to 27.15	1.03 0.02 to 50.78	1.02 0.02 to 57.39	VILDAGLIPTIN	0.99 0.02 to 48.09	0.98 0.02 to 49.85	0.96 0.02 to 54.00	0.97 0.02 to 44.05	0.89 0.02 to 49.46	0.88 0.02 to 51.11	0.93 0.02 to 46.44	0.87 0.02 to 45.72	0.81 0.02 to 29.86	0.72 0.02 to 24.80	0.70 0.03 to 14.29	0.65 0.02 to 19.32	0.48 0.01 to 18.40
ORFO_PO	0.68 0.04 to 10.94	3.95 0.12 to 153	3.70 0.14 to 105	3.64 0.11 to 137	3.45 0.15 to 78.45	2.93 0.07 to 117	2.85 0.08 to 109	2.68 0.08 to 108	2.22 0.05 to 99.19	1.73 0.05 to 61.11	1.72 0.04 to 78.53	1.75 0.04 to 74.32	1.57 0.06 to 32.70	1.40 0.03 to 60.51	1.31 0.03 to 59.93	1.14 0.02 to 58.26	1.11 0.02 to 53.84	1.10 0.02 to 52.80	1.07 0.02 to 51.81	1.15 0.05 to 25.54	1.01 0.02 to 52.13	1.04 0.02 to 56.57	1.01 0.02 to 55.43	ORFO_PO	1.03 0.02 to 48.87	0.99 0.02 to 47.52	0.96 0.02 to 50.06	0.92 0.02 to 46.91	0.94 0.02 to 46.74	0.94 0.02 to 48.72	0.90 0.02 to 44.32	0.84 0.02 to 28.95	0.74 0.02 to 23.95	0.70 0.03 to 15.06	0.67 0.02 to 18.23	0.49 0.01 to 17.20
HRS7535_PO	0.68 0.05 to 10.25	3.84 0.12 to 144	3.63 0.15 to 115	3.59 0.12 to 109	3.33 0.14 to 75.61	2.90 0.08 to 110	2.80 0.09 to 103	2.74 0.08 to 90.30	2.14 0.05 to 88.32	1.68 0.05 to 57.11	1.68 0.04 to 73.74	1.70 0.04 to 65.60	1.55 0.07 to 31.69	1.41 0.03 to 59.28	1.29 0.03 to 51.88	1.13 0.02 to 58.18	1.06 0.02 to 50.08	1.05 0.03 to 49.12	1.06 0.02 to 50.68	1.14 0.06 to 24.69	1.01 0.02 to 42.96	1.01 0.02 to 51.49	1.02 0.02 to 47.60	0.97 0.02 to 52.06	HRS7535_PO	0.98 0.02 to 51.65	0.97 0.02 to 44.36	0.92 0.02 to 40.79	0.90 0.02 to 49.60	0.93 0.02 to 43.13	0.89 0.02 to 42.43	0.80 0.02 to 27.17	0.73 0.02 to 22.89	0.68 0.04 to 14.92	0.66 0.02 to 17.96	0.48 0.01 to 16.27
BOFANG_SC	0.70 0.04 to 11.27	3.99 0.13 to 156	3.88 0.15 to 107	3.77 0.11 to 137	3.37 0.15 to 84.78	3.06 0.08 to 121	2.92 0.09 to 110	2.75 0.08 to 102	2.19 0.06 to 103	1.71 0.05 to 58.03	1.79 0.04 to 84.52	1.74 0.04 to 72.71	1.56 0.07 to 37.41	1.51 0.03 to 61.17	1.37 0.03 to 58.34	1.20 0.02 to 54.01	1.11 0.02 to 53.03	1.12 0.02 to 56.14	1.10 0.02 to 54.54	1.17 0.06 to 27.21	1.06 0.02 to 50.46	1.05 0.02 to 63.19	1.04 0.02 to 52.99	1.01 0.02 to 52.83	1.02 0.02 to 54.49	BOFANG_SC	1.02 0.02 to 48.88	0.95 0.02 to 47.28	0.95 0.02 to 43.44	0.95 0.02 to 52.93	0.91 0.02 to 50.11	0.84 0.02 to 28.35	0.75 0.02 to 28.42	0.71 0.03 to 14.56	0.71 0.02 to 21.19	0.51 0.01 to 17.03
MAZD_SC	0.71 0.04 to 10.97	4.15 0.12 to 145	3.89 0.16 to 112	3.79 0.12 to 147	3.47 0.15 to 75.77	2.98 0.09 to 108	2.90 0.09 to 104	2.76 0.08 to 99.43	2.28 0.06 to 107	1.75 0.05 to 56.43	1.81 0.04 to 78.03	1.72 0.05 to 71.84	1.58 0.07 to 34.79	1.48 0.03 to 63.64	1.32 0.03 to 58.30	1.17 0.02 to 57.84	1.13 0.02 to 56.61	1.10 0.02 to 51.95	1.08 0.02 to 57.35	1.15 0.06 to 25.44	1.09 0.02 to 47.42	1.04 0.02 to 54.68	1.03 0.02 to 53.04	1.05 0.02 to 49.97	1.03 0.02 to 50.88	0.98 0.02 to 51.24	MAZD_SC	0.95 0.02 to 45.26	0.95 0.02 to 45.17	0.93 0.02 to 50.02	0.91 0.02 to 47.47	0.82 0.02 to 28.78	0.76 0.02 to 24.89	0.71 0.04 to 14.48	0.71 0.02 to 20.93	0.50 0.01 to 15.81
OTHER_ACTIVE_additional_OAD	0.74 0.05 to 11.51	4.46 0.13 to 148	4.16 0.16 to 110	4.02 0.13 to 143	3.64 0.17 to 86.71	3.20 0.09 to 118	3.18 0.09 to 112	2.99 0.08 to 121	2.43 0.07 to 104	1.89 0.06 to 66.16	1.87 0.04 to 81.12	1.85 0.05 to 78.88	1.70 0.08 to 34.58	1.55 0.04 to 75.60	1.45 0.03 to 62.69	1.22 0.02 to 64.94	1.21 0.02 to 62.77	1.22 0.03 to 57.66	1.15 0.02 to 63.29	1.27 0.06 to 26.44	1.13 0.02 to 49.21	1.10 0.02 to 62.49	1.12 0.02 to 49.52	1.08 0.02 to 60.54	1.08 0.02 to 56.73	1.05 0.02 to 55.64	1.05 0.02 to 52.41	OTHER_ACTIVE_additional_OAD	0.99 0.02 to 55.22	1.03 0.02 to 58.01	1.00 0.02 to 43.92	0.91 0.02 to 30.80	0.83 0.02 to 24.92	0.75 0.04 to 16.12	0.73 0.03 to 22.02	0.55 0.01 to 16.87
VISEPE_SC	0.74 0.04 to 10.40	4.32 0.12 to 151	4.14 0.15 to 109	3.88 0.12 to 137	3.65 0.15 to 83.39	3.19 0.08 to 112	3.10 0.09 to 109	2.88 0.08 to 104	2.36 0.06 to 88.98	1.88 0.05 to 62.42	1.83 0.04 to 74.95	1.82 0.05 to 72.27	1.69 0.07 to 37.88	1.57 0.04 to 62.05	1.40 0.03 to 57.75	1.22 0.02 to 59.38	1.15 0.02 to 52.76	1.19 0.02 to 53.71	1.15 0.02 to 50.74	1.26 0.06 to 26.15	1.10 0.02 to 53.75	1.12 0.02 to 53.67	1.14 0.02 to 55.57	1.07 0.02 to 53.54	1.11 0.02 to 52.54	1.06 0.02 to 49.80	1.06 0.02 to 51.72	1.01 0.02 to 48.26	VISEPE_SC	1.02 0.02 to 48.55	0.96 0.02 to 47.77	0.87 0.02 to 30.12	0.80 0.02 to 25.90	0.76 0.03 to 16.11	0.73 0.02 to 20.47	0.53 0.01 to 16.48
STANDARD_CARE	0.74 0.04 to 13.23	4.42 0.12 to 157	4.16 0.14 to 127	3.96 0.11 to 158	3.71 0.14 to 93.47	3.24 0.08 to 117	3.09 0.09 to 119	2.93 0.08 to 121	2.42 0.06 to 101	1.86 0.05 to 71.66	1.83 0.04 to 90.44	1.84 0.04 to 86.72	1.73 0.07 to 41.39	1.55 0.04 to 72.05	1.44 0.03 to 65.00	1.20 0.02 to 66.00	1.20 0.02 to 60.96	1.17 0.02 to 67.13	1.16 0.02 to 63.38	1.23 0.06 to 30.46	1.13 0.02 to 55.33	1.10 0.02 to 64.90	1.08 0.02 to 61.24	1.06 0.02 to 60.02	1.07 0.02 to 56.32	1.06 0.02 to 53.80	1.07 0.02 to 56.74	0.97 0.02 to 52.54	0.98 0.02 to 52.18	STANDARD_CARE	0.96 0.02 to 56.45	0.90 0.02 to 31.84	0.83 0.02 to 27.88	0.77 0.03 to 17.37	0.73 0.02 to 23.60	0.54 0.01 to 18.74
OTHER_ACTIVE_basal_bolus_insulin	0.77 0.04 to 12.23	4.50 0.14 to 158	4.35 0.16 to 109	4.14 0.13 to 144	3.83 0.17 to 88.95	3.28 0.09 to 133	3.15 0.09 to 125	3.07 0.08 to 119	2.43 0.06 to 102	1.95 0.06 to 64.42	1.88 0.05 to 87.54	1.90 0.05 to 75.87	1.76 0.08 to 37.69	1.61 0.04 to 69.51	1.45 0.04 to 63.57	1.29 0.03 to 59.30	1.24 0.02 to 56.27	1.22 0.02 to 56.68	1.21 0.02 to 59.67	1.29 0.06 to 27.95	1.15 0.02 to 59.35	1.17 0.02 to 61.58	1.15 0.02 to 51.14	1.11 0.02 to 54.94	1.13 0.02 to 58.86	1.10 0.02 to 59.05	1.10 0.02 to 51.44	1.00 0.02 to 51.92	1.04 0.02 to 53.70	1.04 0.02 to 59.97	OTHER_ACTIVE_basal_bolus_insulin	0.92 0.02 to 33.34	0.84 0.02 to 28.91	0.78 0.04 to 16.50	0.75 0.03 to 24.07	0.56 0.01 to 17.46
EFPE_SC	0.83 0.09 to 8.84	4.91 0.22 to 129	4.51 0.28 to 92.83	4.50 0.20 to 110	4.12 0.29 to 66.81	3.71 0.14 to 99.55	3.45 0.16 to 93.68	3.36 0.13 to 85.90	2.73 0.10 to 78.85	2.09 0.09 to 50.15	2.13 0.06 to 71.65	2.07 0.07 to 59.59	1.91 0.14 to 28.23	1.74 0.06 to 57.48	1.60 0.06 to 51.08	1.36 0.04 to 56.02	1.29 0.04 to 47.03	1.34 0.04 to 50.24	1.34 0.03 to 52.23	1.37 0.11 to 21.23	1.28 0.03 to 46.14	1.27 0.03 to 49.80	1.23 0.03 to 50.04	1.19 0.03 to 51.03	1.24 0.04 to 43.32	1.20 0.04 to 44.83	1.22 0.03 to 43.24	1.09 0.03 to 40.13	1.16 0.03 to 42.75	1.11 0.03 to 47.52	1.08 0.03 to 40.53	EFPE_SC	0.91 0.04 to 22.29	0.84 0.06 to 12.80	0.82 0.04 to 17.34	0.60 0.02 to 14.82
SAFIGL_PO	0.92 0.11 to 8.34	5.22 0.28 to 133	5.09 0.31 to 86.09	5.01 0.25 to 114	4.46 0.34 to 75.04	3.93 0.18 to 97.43	3.84 0.19 to 96.37	3.56 0.16 to 89.58	2.99 0.11 to 81.53	2.31 0.10 to 48.23	2.29 0.08 to 70.33	2.25 0.10 to 67.24	2.07 0.16 to 28.41	1.90 0.08 to 63.28	1.67 0.10 to 41.08	1.47 0.05 to 51.95	1.47 0.04 to 50.87	1.48 0.05 to 49.46	1.41 0.04 to 54.05	1.52 0.14 to 20.90	1.40 0.04 to 45.54	1.39 0.04 to 50.15	1.39 0.04 to 43.21	1.35 0.04 to 44.64	1.37 0.04 to 42.81	1.33 0.04 to 44.95	1.32 0.04 to 42.89	1.20 0.04 to 41.11	1.25 0.04 to 45.03	1.21 0.04 to 48.79	1.20 0.03 to 40.86	1.10 0.04 to 25.81	SAFIGL_PO	0.93 0.08 to 11.67	0.88 0.05 to 18.57	0.67 0.03 to 13.82
ALBI_SC	1.01 0.25 to 3.24	5.72 0.48 to 77.74	5.31 0.68 to 50.98	5.23 0.45 to 70.61	4.76 0.71 to 34.84	4.19 0.29 to 56.58	3.98 0.34 to 58.76	3.80 0.27 to 56.16	3.17 0.20 to 52.31	2.45 0.19 to 30.71	2.41 0.14 to 44.52	2.38 0.19 to 36.47	2.26 0.33 to 14.05	2.01 0.13 to 35.06	1.88 0.11 to 31.37	1.66 0.08 to 33.69	1.55 0.08 to 32.52	1.56 0.07 to 31.42	1.55 0.07 to 32.26	1.56 0.36 to 10.63	1.49 0.06 to 31.85	1.50 0.06 to 32.93	1.42 0.07 to 32.68	1.43 0.07 to 30.43	1.48 0.07 to 27.62	1.40 0.07 to 29.19	1.40 0.07 to 28.19	1.33 0.06 to 24.84	1.32 0.06 to 28.74	1.29 0.06 to 31.07	1.28 0.06 to 26.19	1.19 0.08 to 16.13	1.08 0.09 to 12.15	ALBI_SC	0.98 0.08 to 9.79	0.72 0.05 to 8.34
EXENER_SC	1.01 0.14 to 7.48	5.96 0.33 to 122	5.56 0.46 to 85.33	5.35 0.33 to 112	5.03 0.48 to 58.43	4.23 0.20 to 97.55	4.27 0.22 to 87.31	3.95 0.19 to 91.72	3.23 0.13 to 84.96	2.53 0.14 to 48.24	2.60 0.11 to 70.60	2.54 0.11 to 66.97	2.31 0.20 to 26.23	2.11 0.09 to 58.34	1.96 0.08 to 53.05	1.70 0.05 to 53.96	1.65 0.05 to 44.70	1.64 0.05 to 49.13	1.63 0.06 to 48.96	1.66 0.18 to 20.46	1.54 0.05 to 49.71	1.51 0.04 to 49.21	1.53 0.05 to 47.19	1.50 0.05 to 45.97	1.52 0.06 to 42.77	1.41 0.05 to 43.87	1.41 0.05 to 45.50	1.36 0.05 to 39.10	1.37 0.05 to 42.91	1.37 0.04 to 50.13	1.33 0.04 to 38.61	1.21 0.06 to 26.31	1.13 0.05 to 20.01	1.02 0.10 to 12.55	EXENER_SC	0.74 0.03 to 14.08
TIRZ_SC	1.39 0.16 to 13.37	8.17 0.39 to 193	7.74 0.50 to 131	7.55 0.35 to 176	6.80 0.50 to 112	5.87 0.25 to 158	5.73 0.28 to 137	5.44 0.24 to 142	4.55 0.17 to 119	3.49 0.16 to 85.47	3.55 0.11 to 109	3.33 0.14 to 105	3.18 0.24 to 44.83	3.01 0.11 to 94.61	2.66 0.10 to 75.09	2.27 0.07 to 87.22	2.25 0.07 to 74.81	2.20 0.06 to 73.67	2.15 0.07 to 76.35	2.28 0.22 to 30.62	2.05 0.06 to 69.52	2.08 0.06 to 78.52	2.09 0.05 to 75.86	2.05 0.06 to 74.51	2.06 0.06 to 69.29	1.95 0.06 to 72.49	2.01 0.06 to 70.50	1.83 0.06 to 67.10	1.89 0.06 to 67.81	1.86 0.05 to 72.58	1.79 0.06 to 68.11	1.65 0.07 to 41.62	1.48 0.07 to 33.32	1.40 0.12 to 18.53	1.35 0.07 to 28.79	TIRZ_SC

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.502 (95% CrI 0.099 to 1.387), log scale
Residual deviance: 72.6 for 166 data points
DIC: 95.0 (pD 22.5)
Largest R-hat: 1.003
Smallest ESS: bulk 1,969, tail 3,101
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR06 N(0, 1.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 9 or less
NoteOutcome assessment, time point: selected time points span 0.43 to 365.26 weeks
NoteOutcome assessment, analysis set: mixed: completers 2, full_analysis 1, modified_itt 4, randomized 5, safety 67
NoteOutcome assessment, definition: mixed: ADA severe hypoglycemia 1, adjudicated pancreatitis 1, any hypoglycemia, blood glucose below 70 mg/dL 1, confirmed: severe or plasma glucose below 3.1 mmol/L 1, Hypoglycemia adverse event of special interest 1, hypoglycemia AE with BG 3.9 mmol/L or lower 1, hypoglycemia requiring medical assistance 1, investigator suspected pancreatitis 1, level 3 severe hypoglycemia 2, Major hypoglycemia needing third party assistance or with loss of consciousness 1, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, No severe or below 3 mmol/L hypoglycemia over whole 52 week study 1, not stated 42, plasma glucose 54 mg/dL or lower 1, serious hypoglycemia adverse events 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe (ADA) or plasma glucose confirmed below 3.1 mmol/L 1, severe hypoglycemia 3, severe hypoglycemia by ADA classification 1, Severe hypoglycemia needing another person to give carbohydrate, glucagon or other measures (protocol) 1, severe hypoglycemia needing assistance of another person 1, severe hypoglycemia needing emergency care 1, severe hypoglycemia, self reported 1, severe hypoglycemia, subject unable to treat self 1, severe hypoglycemic events, adverse event of special interest 1, Severe or plasma glucose below 3.1 mmol/L 1, Severe symptomatic hypoglycemia 1, severe symptomatic hypoglycemia needing assistance 2, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery 1, severe, assistance of another person required 1, severe, needing assistance of another person 1, Zero implied by no hypoglycemia episodes of any kind 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: no 5, not stated 62, yes 12
NoteOutcome assessment, proportion method: mixed: not stated 75, observed 4
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 77, treatment_policy 1, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 2, not stated 76, treatment_policy 1
NoteRisk of bias, blinding: mixed: double_blind 53, not_reported 1, open_label 24, single_blind 1
NoteRisk of bias, funding: mixed: industry 72, mixed 1, non_industry 5, not_reported 1
NoteData handling, input conversions: arms_combined 40, printed_denominator 11

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT02081118	22	safety	hypoglycemia AE with BG 3.9 mmol/L or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	not stated	not stated	no	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT00518115	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin
DUAL™ I China	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	Chinese adults 18 y or older; HbA1c 7.0 to 10.0; BMI 40 or less; metformin with or without one OAD
NCT00838916	52	safety	not stated	not stated	yes	not stated	not stated	not stated	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
PIONEER 4	57	safety	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
NCT04965506	24	safety	investigator suspected pancreatitis	not stated	no	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
REWIND	365.26	randomized	Severe hypoglycemia needing another person to give carbohydrate, glucagon or other measures (protocol)	not stated	not stated	not stated	treatment_policy	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
STEP HFpEF DM	57	safety	serious hypoglycemia adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
DUAL™IV	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults 18 or older; HbA1c 7.0 to 9.0 percent; BMI 40 or less; SU with or without metformin; insulin and GLP-1 RA naive
NCT01476475	24	safety	Severe symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB119	24	safety	No severe or below 3 mmol/L hypoglycemia over whole 52 week study	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT02846233	16	randomized	any hypoglycemia, blood glucose below 70 mg/dL	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2016	age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin
NCT01149421	26	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT01584232	26	safety	severe, needing assistance of another person	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
AWARD-10	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin
NCT01029886	26	modified_itt	Major hypoglycemia needing third party assistance or with loss of consciousness	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
NCT00976937	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
AWARD-9	28	safety	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2014	adults with T2D on basal insulin glargine with or without metformin
NCT05579977	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
GETGOAL-L-ASIA	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT00612794	20	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	Japanese T2D age 20 to 75; weight 50 kg or more; HbA1c 6.5 to 10 percent; diet or oral drugs
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
NCT02008682	26	safety	Severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	Chinese adults 18 to 80; HbA1c 7.0 to 10.0 on metformin; BMI 45 or lower
NCT02229383	38	safety	minor: symptomatic, glucose below 3.0 mmol/L, not major	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT01558271	52	safety	severe, assistance of another person required	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT00395746	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
NCT01617434	27	safety	severe hypoglycemia, subject unable to treat self	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin
LIRA-Ramadan™	30	safety	confirmed: severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
AWARD-CHN1	30.29	safety	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	28.29	modified_itt	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT02465515	140.89	safety	severe hypoglycemic events, adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	type 2 diabetes with established cardiovascular disease
AWARD-2	78	safety	adjudicated pancreatitis	not stated	yes	not stated	not stated	not stated	open_label	industry	2010	type 2 diabetes on metformin and glimepiride
DURATION-NEO-2	28	safety	minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-6	30	safety	not stated	not stated	yes	not stated	not stated	not stated	open_label	industry	2012	adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
NCT03985293	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT01191268	52	safety	not stated	not stated	not stated	not stated	not stated	hypothetical	open_label	industry	2010	adults with type 2 diabetes on conventional insulin with or without metformin
DUALTM IX	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; insulin naive type 2 diabetes on SGLT2 inhibitor with or without other oral drugs; HbA1c 7.0 to 11.0 percent; BMI 20 to 40
SUSTAIN	35	safety	Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
AWARD-CHN2	52	safety	not stated	not stated	yes	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
GETGOAL-X	24	safety	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT00299871	13.43	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
SUSTAIN™	62	safety	ADA severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
LEAD-2	26	safety	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
DUAL™ II China	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 24 or higher; HbA1c 7.5 or higher; basal insulin 20 to 50 U plus metformin
NCT00744926	24	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
NCT01126580	56.29	safety	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2010	type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
PIONEER 11	31	safety	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
SUSTAIN™ 5	35	safety	not stated	not stated	yes	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
NCT02229227	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
NCT00382239	12	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
AGAC2	0.43	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2011	age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
NCT00423501	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; metformin 1500 mg or more; HbA1c 7 to 9.5 percent; BMI 25 to 45
DUAL™ II Japan	27	safety	severe (ADA) or plasma glucose confirmed below 3.1 mmol/L	not stated	not stated	observed	not stated	not stated	double_blind	industry	2016	Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™	35	safety	severe hypoglycemia by ADA classification	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
LEAD-5	27	safety	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
AWARD-1	52	safety	severe hypoglycemia, self reported	not stated	yes	not stated	not stated	not stated	double_blind	industry	2010	adults with type 2 diabetes on metformin and pioglitazone
NCT01455441	16	completers	Zero implied by no hypoglycemia episodes of any kind	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	age over 18; HbA1c 7 to 11 percent; BMI over 25; diet or metformin; sedentary
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT06256523	29	safety	not stated	not stated	no	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S002947	25	safety	not stated	not stated	no	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S002951	16	safety	not stated	not stated	no	not stated	not stated	not stated	open_label	non_industry	2022	age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
S003072	14	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2011	age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months
S003437	24	randomized	severe hypoglycemia needing emergency care	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2025	knee osteoarthritis Kellgren Lawrence I to III; obesity; metabolic syndrome; type 2 diabetes for randomized groups

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	0 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	2 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	0 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	0 / 388	arms_combined	R0022521:Results
NCT00754988	A4	SITAGLIPTIN	156	arm, events	0 / 185		R0022521:Results
NCT00518115	A1	PLACEBO	24	arm, events	0 / 52		R0015772:Results
NCT00518115	A10+A3+A4+A5+A6+A7+A8+A9	ALBI_SC	24	arm, events	0 / 274	arms_combined	R0015772:Results
NCT00518115	A2	EXEN_SC	24	arm, events	0 / 35		R0015772:Results
DUAL™ I China	A1	IDEGLIRA_SC	26	arm, events	0 / 361		R0012560:Results
DUAL™ I China	A2	INS_DEGLUDEC	26	arm, events	0 / 179		R0012560:Results
DUAL™ I China	A3	LIRA_SC	26	arm, events	0 / 180		R0012560:Results
NCT00838916	A1	ALBI_SC	52	arm, events	0 / 516		R0025374:p6
NCT00838916	A2	INS_GLARGINE	52	arm, events	0 / 263		R0025374:p6
PIONEER 4	A1	SEMA_PO	57	arm, events	0 / 285		R0015836:Supplement Table S8
PIONEER 4	A2	LIRA_SC	57	arm, events	1 / 284		R0015836:Supplement Table S8
PIONEER 4	A3	PLACEBO	57	arm, events	1 / 142		R0015836:Supplement Table S8
NCT04965506	A1+A2+A3	MAZD_SC	24	arm, events	0 / 149	arms_combined	R0012443:Results
NCT04965506	A4	DULA_SC	24	arm, events	0 / 50		R0012443:Results
NCT04965506	A5	PLACEBO	24	arm, events	0 / 51		R0012443:Results
REWIND	A1	PLACEBO	365.26	arm, events	13 / 4,952		R0018537:Table 3
REWIND	A2	DULA_SC	365.26	arm, events	23 / 4,949		R0018537:Table 3
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	0 / 198		R0024063:Results
SCALE™ Insulin	A2	PLACEBO	58	arm, events	1 / 198		R0024063:Results
STEP HFpEF DM	A1	SEMA_SC	57	arm, events	2 / 310		R0020223:Supplement Table S9
STEP HFpEF DM	A2	PLACEBO	57	arm, events	0 / 306		R0020223:Supplement Table S9
DUAL™IV	A1	IDEGLIRA_SC	27	arm, events	0 / 289		R0015199:Results
DUAL™IV	A2	PLACEBO	27	arm, events	0 / 146		R0015199:Results
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	0 / 161		R0021236:p5
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:p5
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, events	1 / 212	arms_combined	R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	0 / 72		R0011607:Table 3
PB119	A1	VISEPE_SC	24	arm, events	0 / 137		R0011471:Results
PB119	A2	PLACEBO	24	arm, events	0 / 136		R0011471:Results
NCT01001104	A1	PLACEBO	16	arm, events	0 / 37		R0015000:Results
NCT01001104	A2+A3+A4	DULA_SC	16	arm, events	0 / 108	arms_combined	R0015000:Results
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	0 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	57	arm, events	0 / 65		R0018421:Table 2
NCT02846233	A1	DULA_SC	16	arm, events	0 / 12		R0028441:Table 5
NCT02846233	A2	OTHER_ACTIVE_basal_bolus_insulin	16	arm, events	0 / 10		R0028441:Table 5
NCT01584232	A1	DULA_SC	26	arm, events	0 / 181		R0016159:Results
NCT01584232	A2	INS_GLARGINE	26	arm, events	0 / 180		R0016159:Results
AWARD-10	A1+A2	DULA_SC	24	arm, events	0 / 284	arms_combined	R0020348:p1
AWARD-10	A3	PLACEBO	24	arm, events	0 / 140		R0020348:p1
NCT01029886	A1	EXENER_SC	26	arm, events	1 / 461		R0016299:Results
NCT01029886	A2	LIRA_SC	26	arm, events	0 / 451		R0009388:Supplement Table S4
NCT00976937	A1	LIXI_SC	24	arm, events	0 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	0 / 161		R0012687:Table 2
AWARD-9	A1	DULA_SC	28	arm, events	0 / 150		registry:outcomes
AWARD-9	A2	PLACEBO	28	arm, events	0 / 150		registry:outcomes
NCT05579977	A1+A8	PLACEBO	28	arm, events	0 / 139	arms_combined	R0004106:Results
NCT05579977	A10+A11+A12+A13+A2+A3+A4+A5+A6+A9	LOTI_PO	28	arm, events	0 / 690	arms_combined	R0004106:Results
NCT05579977	A7	SEMA_PO	28	arm, events	0 / 73		R0004106:Results
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	0 / 154		R0022626:Results
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	0 / 157		R0022626:Results
NCT00612794	A1	PLACEBO	20	arm, events	0 / 10	printed_denominator	R0027116:p5
NCT00612794	A2+A3	EXENER_SC	20	arm, events	0 / 19	printed_denominator;arms_combined	R0027116:p5
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	1 / 608	arms_combined	R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	0 / 202		R0029347:Table 3
NCT02008682	A1	LIRA_SC	26	arm, events	0 / 184		R0025836:Results
NCT02008682	A2	SITAGLIPTIN	26	arm, events	0 / 184		R0025836:Results
NCT02229383	A1	EXENER_SC	38	arm, events	1 / 233		R0014763:Table 3
NCT02229383	A2	PLACEBO	38	arm, events	0 / 231		R0014763:Table 3
NCT02081118	A1	PLACEBO	22	arm, events	0 / 51		R0009733:Results
NCT02081118	A2+A3+A4	EFPE_SC	22	arm, events	0 / 157	printed_denominator;arms_combined	R0009733:Results
NCT01149421	A1+A2	DULA_SC	26	arm, events	0 / 505	arms_combined	registry:outcomes
NCT01149421	A3	PLACEBO	26	arm, events	0 / 250		registry:outcomes
NCT01558271	A1	DULA_SC	52	arm, events	0 / 281		R0011754:Results
NCT01558271	A2	LIRA_SC	52	arm, events	0 / 141		R0011754:Results
NCT00849017	A1	PLACEBO	52	arm, events	0 / 105		R0022386:Results
NCT00849017	A2+A3	ALBI_SC	52	arm, events	0 / 204	arms_combined	R0022386:Results
NCT00395746	A1+A2	LIRA_SC	52	arm, events	0 / 178	arms_combined	R0022802:Results
NCT00395746	A3	PLACEBO	52	arm, events	0 / 89		R0022802:Results
NCT05759897	A1	PLACEBO	16	arm, events	0 / 39	printed_denominator	R0002101:Table 3
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	0 / 155	printed_denominator;arms_combined	R0002101:Table 3
NCT01617434	A1	LIRA_SC	27	arm, events	0 / 226		R0026247:Results
NCT01617434	A2	PLACEBO	27	arm, events	0 / 225		R0026247:Results
LIRA-Ramadan™	A1	LIRA_SC	30	arm, events	0 / 172		R0025756:Results
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	0 / 171		R0025756:Results
AWARD-CHN1	A1+A2	DULA_SC	30.29	arm, events	0 / 492	arms_combined	R0014229:Results
AWARD-CHN1	A3	GLIMEPIRIDE	30.29	arm, events	0 / 245		R0014229:Results
AWARD-8	A1	DULA_SC	28.29	arm, events	0 / 240		registry:outcomes
AWARD-8	A2	PLACEBO	28.29	arm, events	0 / 60		registry:outcomes
NCT02465515	A1	PLACEBO	140.89	arm, events	7 / 4,732		registry:outcomes
NCT02465515	A2	ALBI_SC	140.89	arm, events	10 / 4,731		registry:outcomes
AWARD-2	A1+A2	DULA_SC	78	arm, events	3 / 545	arms_combined	registry:outcomes
AWARD-2	A3	INS_GLARGINE	78	arm, events	0 / 265		registry:outcomes
DURATION-NEO-2	A1	EXENER_SC	28	arm, events	0 / 182		R0010641:Table 3
DURATION-NEO-2	A2	SITAGLIPTIN	28	arm, events	0 / 122		R0010641:Table 3
DURATION-NEO-2	A3	PLACEBO	28	arm, events	0 / 61		R0010641:Table 3
NCT05514535	A1	SEMA_SC	45	arm, events	1 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	1 / 285		R0015842:Table 2
AWARD-6	A1	DULA_SC	30	arm, events	0 / 299		registry:outcomes
AWARD-6	A2	LIRA_SC	30	arm, events	0 / 300		registry:outcomes
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66		R0006095:Results
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	0 / 346	arms_combined	R0006095:Results
NCT01191268	A1+A2	DULA_SC	52	arm, events	0 / 588	arms_combined	registry:outcomes
NCT01191268	A3	INS_GLARGINE	52	arm, events	0 / 296		registry:outcomes
DUALTM IX	A1	IDEGLIRA_SC	27	arm, events	0 / 210		R0014323:Results
DUALTM IX	A2	INS_GLARGINE	27	arm, events	0 / 210		R0014323:Results
SUSTAIN	A1+A2	SEMA_SC	35	arm, events	1 / 578	arms_combined	R0014802:Table 3
SUSTAIN	A3	SITAGLIPTIN	35	arm, events	0 / 290		R0014802:Table 3
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	0 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	0 / 94		R0004355:Table 2
AWARD-CHN2	A1+A2	DULA_SC	52	arm, events	0 / 515	arms_combined	R0023722:Results
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	0 / 259		R0023722:Results
GETGOAL-X	A1	LIXI_SC	24	arm, events	0 / 320		R0022279:Results
GETGOAL-X	A2	EXEN_SC	24	arm, events	0 / 319		R0022279:Results
NCT00299871	A1	PLACEBO	13.43	arm, events	0 / 109		R0021613:Results
NCT00299871	A2+A3+A4+A5+A6+A7+A8+A9	LIXI_SC	13.43	arm, events	0 / 433	arms_combined	R0021613:Results
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	0 / 480	arms_combined	R0025024:Results
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	0 / 121		R0025024:Results
LEAD-2	A2	LIRA_SC	26	arm, events	1 / 241		R0019848:Results
LEAD-2	A4	GLIMEPIRIDE	26	arm, events	1 / 244		R0019848:Results
NCT05486065	A1+A2+A3	SEMA_SC	49	arm, events	1 / 185	arms_combined	R0005510:Table 2
NCT05486065	A4	PLACEBO	49	arm, events	1 / 60		R0005510:Table 2
DUAL™ II China	A1	IDEGLIRA_SC	30	arm, events	0 / 302		R0012135:Results
DUAL™ II China	A2	INS_DEGLUDEC	30	arm, events	0 / 151		R0012135:Results
NCT00744926	A1	PLACEBO	24	arm, events	0 / 123	printed_denominator	R0025346:Results
NCT00744926	A2+A3	TASP_SC	24	arm, events	0 / 245	printed_denominator;arms_combined	R0025346:Results
NCT01126580	A1+A2	DULA_SC	56.29	arm, events	0 / 539	arms_combined	registry:outcomes
NCT01126580	A3	METFORMIN	56.29	arm, events	0 / 268		registry:outcomes
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	0 / 390	arms_combined	R0019663:Supplement Table 6
PIONEER 11	A4	PLACEBO	31	arm, events	0 / 131		R0019663:Supplement Table 6
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	0 / 264	arms_combined	R0012671:Results
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	0 / 133		R0012671:Results
NCT02229227	A1	ALBI_SC	26	arm, events	1 / 402		R0008089:Results
NCT02229227	A2	INS_LISPRO	26	arm, events	0 / 412		R0008089:Results
NCT00382239	A1	PLACEBO	12	arm, events	0 / 40		R0027621:p7
NCT00382239	A2+A3+A4	EXEN_SC	12	arm, events	0 / 113	arms_combined	R0027621:p7
AGAC2	A1	PLACEBO	0.43	arm, events	0 / 21		R0020827:Results
AGAC2	A2	EXEN_SC	0.43	arm, events	0 / 30		R0020827:Results
NCT01632163	A1	LIXI_SC	24	arm, events	0 / 224		R0014725:Results
NCT01632163	A2	PLACEBO	24	arm, events	0 / 224		R0014725:Results
NCT05086445	A1	PLACEBO	14	arm, events	0 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	0 / 49	arms_combined	R0003844:Table 2
NCT00423501	A1	PLACEBO	12	arm, events	0 / 49	printed_denominator	R0022337:Results
NCT00423501	A2+A3+A4+A5+A6	TASP_SC	12	arm, events	0 / 248	printed_denominator;arms_combined	R0022337:Results
DUAL™ II Japan	A1	IDEGLIRA_SC	27	arm, events	0 / 105		R0015589:Results
DUAL™ II Japan	A2	INS_DEGLUDEC	27	arm, events	0 / 105		R0015589:Results
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	1 / 304	arms_combined	R0007136:Results
AMPLITUDE-M	A4	PLACEBO	56	arm, events	0 / 102		R0007136:Results
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	0 / 205	arms_combined	R0014736:Results
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	0 / 103		R0014736:Results
LEAD-5	A1	LIRA_SC	27	arm, events	0 / 232		R0027336:Results
LEAD-5	A2	PLACEBO	27	arm, events	0 / 115		R0027336:Results
LEAD-5	A3	INS_GLARGINE	27	arm, events	0 / 234		R0027336:Results
AWARD-1	A1+A2	DULA_SC	52	arm, events	1 / 559	arms_combined	registry:outcomes
AWARD-1	A3	EXEN_SC	52	arm, events	0 / 278		registry:outcomes
NCT01455441	A1	LIRA_SC	16	arm, events	0 / 18		R0010221:Results
NCT01455441	A2	PLACEBO	16	arm, events	0 / 16		R0010221:Results
NCT03311724	A1	PLACEBO	16	arm, events	0 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	0 / 85	arms_combined	R0010282:Table 2
NCT06256523	A1	BOFANG_SC	29	arm, events	0 / 27	printed_denominator	R0002476:Results
NCT06256523	A2	PLACEBO	29	arm, events	0 / 9	printed_denominator	R0002476:Results
S002946	A1	SEMA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002947	A1+A2+A3	ECNO_SC	25	arm, events	0 / 109	arms_combined	R0006482:Results
S002947	A4	PLACEBO	25	arm, events	0 / 36		R0006482:Results
S002951	A1	PEGLOX_SC	16	arm, events	0 / 104		R0007588:Results
S002951	A2	METFORMIN	16	arm, events	0 / 52		R0007588:Results
S003072	A1	VILDAGLIPTIN	14	arm, events	0 / 62		R0023470:Results
S003072	A2	LIRA_SC	14	arm, events	0 / 60		R0023470:Results
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results
S003437	A1	METFORMIN	24	arm, events	0 / 60		R0053478:Results
S003437	A2+A3	SEMA_SC	24	arm, events	0 / 120	arms_combined	R0053478:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab